As our erlotinib-treated PIK3CA-comutated case, these data suggest that PIK3CA-mutations despite being considered cancer-drivers do not necessarily represent a mechanism of primary resistance to erlotinib in EGFR-mutated NSCLC. This evidence concerns the gene PIK3CA and cancer.